Top Markets
#1 Galxe Galxe +86.35%
#2 Gravity Gravity +67.36%
#3 Akedo Akedo +66.92%
#4 Railgun Railgun +39.44%
#5 Bedrock Bedrock +37.89%
#6 Pearl Pearl +36.88%
#7 TENDIES TENDIES +35.93%
#8 Starknet Starknet +32.02%
#9 MYX Finance MYX Finance +30.01%
#10 Pieverse Pieverse +27.64%
Coin of the day
Galxe Galxe
Settings
Language
ENGLISH
Currency
USD
Theme
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVXA
Rank in Stocks #38483
Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc... Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc operates as a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market innovative therapies for various female sexual dysfunctions. Its primary drug candidate, BP-101, is being developed as a medical treatment for premenopausal women diagnosed with hypoactive sexual desire disorder. This compound is presently in Phase II clinical investigation in Australia and New Zealand, and has progressed to Phase III clinical trials within Russia. Beyond its core pharmaceutical work, the company also participates in mineral exploration and offers supplementary support services. The organization, originally incorporated as Ovoca Gold plc, rebranded to Ovoca Bio plc in July 2018.
Share Price
$0.01142111
Last synced: 2025-03-21
Market Cap
$930.66K
Change (1 day)
0.18%
Change (1 year)
-69.73%
Country
IE
Trade Ovoca Bio plc (OVXA)

Category

Healthcare
Revenue for Ovoca Bio plc (OVXA)
Revenue in Jun 2024 TTM: 0.00
According to Ovoca Bio plc latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 equal to the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ovoca Bio plc from 2001 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 0.00%
2001 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH